Watada H

Title : Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice - Ervinna_2013_Endocrinology_154_1260

Author(s) : Ervinna N , Mita T , Yasunari E , Azuma K , Tanaka R , Fujimura S , Sukmawati D , Nomiyama T , Kanazawa A , Kawamori R , Fujitani Y , Watada H

Ref : Endocrinology , 154 :1260 , 2013

Abstract :

PubMedSearch : Ervinna_2013_Endocrinology_154_1260

PubMedID: 23337530

Title : Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients - Horie_2011_Clin.Ther_33_973

Author(s) : Horie Y , Kanada S , Watada H , Sarashina A , Taniguchi A , Hayashi N , Graefe-Mody EU , Woerle HJ , Dugi KA

Ref : Clin Ther , 33 :973 , 2011

Abstract :

PubMedSearch : Horie_2011_Clin.Ther_33_973

PubMedID: 21723606

Watada H

References (2)

1. Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice - Ervinna_2013_Endocrinology_154_1260

2. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients - Horie_2011_Clin.Ther_33_973